Allgens(SH:688613) 智通财经网·2026-02-27 08:14Core Viewpoint - Aojing Medical (688613.SH) reported a revenue of 224 million yuan for the year 2025, marking an 8.48% year-on-year growth, and achieved a net profit of 13.15 million yuan, turning from loss to profit [1] Group 1: Financial Performance - The total operating revenue for 2025 reached 224 million yuan, reflecting an 8.48% increase compared to the previous year [1] - The net profit attributable to the parent company was 13.15 million yuan, indicating a turnaround from previous losses [1] Group 2: Factors Influencing Performance - The orthopedic artificial bone procurement provided opportunities for clinical usage to continue increasing and further expand market share [1] - The company strengthened its production guarantee system to ensure stable fulfillment of the increased demand resulting from procurement [1] Group 3: Marketing Strategy - The company continued to deepen its regional market strategy through refined management and precise marketing tactics, consistently broadening its sales network [1] - The overall revenue growth demonstrated a steady upward trend, further solidifying the company's leading position in the niche market [1]